This comprehensive case study explores Kymanox’s approach to complete pharmaceutical product reformulation through integrated formulation development, manufacturing process design, and regulatory strategy. Our team of Subject Matter Experts (SMEs) collaborated closely with mid-size pharmaceutical stakeholders to implement measurable improvements across ingredient selection, formulation design, process validation, equipment qualification, and registration batch manufacturing for orphan drug patient compliance enhancement.
CHALLENGE
SOLUTION
RESULTS
- Mid-size pharmaceutical company required complete reformulation of orphan drug improving patient compliance and therapeutic adherence for rare disease population.
- Project demanded comprehensive overhaul of formulation composition and manufacturing processes while maintaining strict adherence to FDA regulatory standards.
- Accelerated development timeline essential enabling timely market access for reformulated product serving patients with limited treatment options.
- Integrated regulatory strategy required minimizing approval hurdles and ensuring efficient FDA communication throughout development and submission process.
- Conducted comprehensive ingredient and packaging material selection and sourcing identifying components optimizing patient compliance, stability, and manufacturability.
- Designed innovative formulation and change parts improving product performance, patient acceptability, and therapeutic outcomes.
- Developed and validated robust manufacturing process ensuring scalability, reproducibility, and compliance with CGMP.
- Qualified production equipment to meet stringent manufacturing standards supporting commercial-scale production and regulatory requirements.
- Validated analytical methods ensuring compliance, reliability, and regulatory acceptance for product testing and release.
- Successfully manufactured registration batches meeting all quality specifications and regulatory requirements for submission.
- Implemented strategic regulatory approach minimizing potential hurdles and maintaining effective ongoing communication with FDA throughout project lifecycle.
- Successfully completed comprehensive development and manufactured registration batches within aggressive 12-month timeline from project kickoff.
- Enabled client to achieve reformulation goals efficiently and effectively supporting improved patient compliance for orphan drug indication.
- Delivered validated manufacturing process and qualified equipment supporting seamless transition to commercial production.
- Established clear regulatory pathway through proactive FDA communication and strategic planning minimizing approval timeline.
- Provided mid-size pharmaceutical company with enhanced product addressing unmet patient needs in orphan disease population.